Search Results 1101-1110 of 16413 for monoclonal antibody

1. NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS - Mayo Clinic

   ... monoclonal antibody, including gemtuzumab ozogamicin, 28 days prior to the first dose of NKX101 Note: Treatment with hydroxyurea is allowed up to 48 hours ...

2. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ - Mayo Clinic

   History of severe allergic or anaphylactic reaction to monoclonal antibody therapy. Confirmed diagnosis of progressive multifocal leukoencephalopathy ...

3. A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis - Mayo Clinic

   Known allergies, hypersensitivity, or intolerance to monoclonal antibodies, hyaluronidase, human proteins, or their excipients (refer to IB), or known ...

4. Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma - Mayo Clinic

   Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half-lives prior to ...

5. Axicabtagene Ciloleucel Expanded Access Study - Mayo Clinic

   anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative; and; an anthracycline containing chemotherapy regimen. No evidence ...

6. Open-label Trial of Daratumumab in Treatment of PGNIMD and C3 GN - Mayo Clinic

   ... monoclonal immune deposits (PGNMID) and C3 glomerulopathy associated with monoclonal gammopathy (C3GN). This is an inflammatory disease in the kidney due to ...

7. A Study to Assess the Effectiveness and Safety of Ublituximab in combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) - Mayo Clinic

   ... antibody (HCV ... History of anaphylaxis (excluding infusion related reactions) in association with previous anti-CD20 monoclonal antibody administration.

8. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   ... monoclonal antibodies or Chimeric Antigen Receptor (CAR) T-cell therapy; Patients with a chronic condition requiring the use of systemic corticosteroids at a ...

9. International Group Publishes Updated Criteria for Diagnosing Multiple Myeloma

   Rajkumar said multiple myeloma is always preceded sequentially by two asymptomatic conditions, monoclonal gammopathy of undetermined significance (MGUS) and ...

10. Overview - T Cell Engineering Laboratory - Mayo Clinic Research

    A chimeric antigen receptor is a synthetic antibody on the surface of T cells that enables T cells to recognize cancer cells. The most successful CAR -T ...